From d52fc75d6d930615e75d034865d30f024c58c92a Mon Sep 17 00:00:00 2001
From: Max Luca Beckmann <mbeckmann@techfak.de>
Date: Sat, 28 Sep 2024 16:43:29 +0200
Subject: [PATCH] description sources
---
src/contents/description.tsx | 6 +++---
1 file changed, 3 insertions(+), 3 deletions(-)
diff --git a/src/contents/description.tsx b/src/contents/description.tsx
index 1a467a18..74e88cc2 100644
--- a/src/contents/description.tsx
+++ b/src/contents/description.tsx
@@ -44,9 +44,9 @@ export function Description() {
<SupScrollLink label="1"/>.</p>
<p> It is caused by mutations in the CFTR gene, which controls ions and water movement in cells. This leads to thick mucus, clogging airways, and frequent infections. The defective CFTR protein impacts the respiratory and digestive systems, causing chronic lung infections, breathing difficulties, and malnutrition. CF's severity varies, but it reduces life quality and expectancy. There are over 1,700 CFTR mutations; the F508del mutation is most common, present in 70% of cases. It prevents proper protein folding, affecting its function. </p>
<Collapsible id="fanzorcas-collapsible" title="Cas vs. Fanzor">
- <p>The mutations can be divided into six classes [9]:</p>
+ <p>The mutations can be divided into six classes <SupScrollLink label="9"/>:</p>
<p>Class I mutations prevent the synthesis of CFTR proteins altogether, meaning no channels are produced.</p>
- <p>Class II mutations, which include the common F508del mutation (responsible for about 85% of cases [10]), disrupt the maturation process of the protein. As a result, the defective channels are quickly degraded by the cell.</p>
+ <p>Class II mutations, which include the common F508del mutation (responsible for about 85% of cases <SupScrollLink label="10"/>), disrupt the maturation process of the protein. As a result, the defective channels are quickly degraded by the cell.</p>
<p>Class III mutations, known as “gating†mutations, reduce the likelihood that the CFTR channel will open correctly, impairing its function.</p>
<p>Class IV, V, and VI mutations are rare. These mutations result in the production of unstable or inefficient CFTR proteins, which do not function adequately and are produced in insufficient numbers.</p>
</Collapsible>
@@ -143,7 +143,7 @@ export function Description() {
</div>
</Subesction>
<Subesction title="Treatment" id="Cystic Fibrosis6">
- <p>Cystic fibrosis therapy means inevitably a complex and customized treatment plan for each patient. It consists of a range of components. These include medication such as CFTR modulators and antibiotics as well as inhalation therapy and mucolytics, physiotherapy, nutritional therapy and sports therapy. It is therefore essential that CF patients receive treatment at a specialist centre [1].</p>
+ <p>Cystic fibrosis therapy means inevitably a complex and customized treatment plan for each patient. It consists of a range of components. These include medication such as CFTR modulators and antibiotics as well as inhalation therapy and mucolytics, physiotherapy, nutritional therapy and sports therapy. It is therefore essential that CF patients receive treatment at a specialist centre <SupScrollLink label="1"/>.</p>
<Collapsible id="drugs-collapsible" title="Different types of drugs" >
<TabButtonRow data={medibuttonrowdata} opentype="symptabs" closing=""/>
<ButtonRowTabs data={medibuttonrowdata} cla="symptabs"/>
--
GitLab